07:39 AM EDT, 06/24/2025 (MT Newswires) -- Amarin ( AMRN ) said Tuesday it signed an exclusive license and supply agreement with Recordati to commercialize Vazkepa in 59 European countries.

Under the terms of the deal, Amarin ( AMRN ) will receive $25 million upfront and up to $150 million in certain milestone-based payments. Recordati will be responsible for the product's commercialization in Europe.

Amarin ( AMRN ) said it will immediately launch a global restructuring as it seeks to streamline its global operations to drive an estimated $70 million in cost savings over the next 12 months.

Vascepa was launched in the US in January 2020 to treat high-risk patients with persistent cardiovascular risk despite being on statin therapy.

Amarin ( AMRN ) shares were up 6.8% in recent premarket activity.